Yumanity Therapeutics WKN: A2AEME ISIN: US74373B1098 Kürzel: 42P Forum: Aktien Thema: Hauptdiskussion

War der Anfangskurs. 😉

Was ne verarsche der Laden!!!

Tja, ich denk ich werd nach neujahr wieder ne kleine posi starten, soll ja im q1 dann mal paar jmty news bzgl ph1 geben, könnte bei guten daten dann ne ordentliche rakete drinnen sein, aber davor wird es noch n bissl runter gehn 🙄 Typischer reverse merger, leider.... Bin auf das risiko, keine cvr anteile und boni zu bekommen, mit verlust raus, hab mir schon sowas gedacht.... Echt bitter

Warum ist hier so tod?

Und was hat denn jetzt yumanity mit proteostasis gemeinsam?

22🥶 ja genau

Isin US98872L1026

Bei Stocktwits zeigt es schon den neuen Kurs an. 22+👍

Habt ihr die aktuellen YMTX Namen schon auf dieser Plattform gefunden? Auf yahoo funktionierts...

Mal schauen was noch so passiert. Wenn nicht gibts halt ein Long Invest😁

1:20 hätte mir besser gefallen 😳

Das war sogar weniger als erwartet 🤔

20:1 Split

BOSTON , Dec. 22, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. ("Proteostasis") (Nasdaq: PTI) announced today that, based on the final vote count certified by the inspector of elections at its reconvened special meeting of stockholders held at 9:00 a.m. Eastern Time on December 22, 2020 (the "Special Meeting"), its stockholders approved all of the proposals related to the merger (the "Merger") as contemplated by the Agreement and Plan of Merger and Reorganization, dated August 22, 2020 , as amended, by and among Proteostasis, Yumanity Holdings, LLC ("Holdings"), Yumanity Therapeutics, Inc. ("Yumanity"), a wholly-owned subsidiary of Holdings, and Pangolin Merger Sub, a wholly-owned subsidiary of Proteostasis ("Merger Sub") (the "Merger Agreement"), including (i) the issuance of Proteostasis common stock in the Merger in accordance with the terms of the Merger Agreement; (ii) a reverse stock split of Proteostasis common stock, at a ratio of one new share for every 20 to 30 shares outstanding, with the exact ratio and effective time of the reverse stock split to be determined by the Proteostasis board of directors and publicly announced by press release; and (iii) an amendment to the Proteostasis certificate of incorporation to effect the change of name from "Proteostasis Therapeutics, Inc." to "Yumanity Therapeutics, Inc." Also approved was the compensation that will or may become payable by Proteostasis to its named executive officers in connection with the Merger, on a non-binding advisory vote basis. Proteostasis' Board of Directors has determined to effect a reverse stock split of the Proteostasis common stock at a ratio of 1-for-20. Therefore, every 20 shares of Proteostasis common stock issued and outstanding immediately prior to the effective time of the reverse stock split will automatically be combined at the effective time into one fully paid and nonassessable share of Proteostasis common stock. The reverse stock split is expected to become effective at 12:00 p.m. Eastern Time on December 22, 2020 . Subject to the satisfaction of customary closing conditions, the Merger is expected to close shortly following the effectiveness of the reverse stock split. Assuming effectiveness of the reverse stock split and closing of the Merger, Proteostasis will be renamed Yumanity Therapeutics, Inc. and Yumanity's common stock will commence trading on the Nasdaq Capital Market on a post-reverse stock split basis under the new symbol "YMTX" on, December 23, 2020 . The CUSIP number for Yumanity's common stock will be 98872L 102. About Yumanity Therapeutics Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company's most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson's disease. Yumanity's drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity's pipeline consists of additional programs focused on Lewy body dementia, multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease. For more information, please visit www.yumanity.com

Rs?